GnRH Agonist Use for Triggering Ovulation and Supporting Luteal Phase in IVF and Frozen Embryo Transfer for Women with Subfertility

What this Trial Is About

Researchers are comparing two methods to improve live birth rates in women undergoing IVF and frozen embryo transfer FET. The study evaluates the use of a dual trigger GnRH agonist plus hCG versus hCG alone for IVF, and GnRH agonist versus placebo for luteal phase support in FET. This is a randomized, double-blinded, placebo-controlled Phase 3 trial focusing on women with subfertility. Women undergoing IVF will receive ovarian stimulation and monitoring before being randomly assigned to receive either the dual trigger recombinant hCG with decapeptyl or hCG with saline injection. Egg retrieval follows 36 hours later, with embryo transfer occurring 2 or 5 days afterward. In the FET group, women will be randomized to receive either decapeptyl or saline on the day of embryo transfer, with embryos transferred 3 or 6 days after the LH surge. Both groups receive standard embryo culture and transfer protocols. Participants will have pregnancy tests 18 days after treatment, followed by ultrasounds to confirm pregnancy and fetal viability. Data on pregnancy outcomes, including delivery details and complications, will be collected from hospital records or private obstetricians. The study closely tracks live birth rates and other pregnancy outcomes, with follow-up continuing through delivery and neonatal assessments.

GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET